Responses
Correspondence response
Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier
Compose a Response to This Article
Other responses
No responses have been published for this article.